Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MorphoSys Completes Sale of AbD Serotec to Bio-Rad

Published: Friday, January 11, 2013
Last Updated: Friday, January 11, 2013
Bookmark and Share
All assets and liabilities of the AbD Serotec have been transferred to Bio-Rad.

MorphoSys AG has announced that the sale of its research and diagnostic antibody segment AbD Serotec to Bio-Rad Laboratories, Inc. has been completed.

All assets and liabilities of the AbD Serotec segment of MorphoSys AG as well as all shares of the subsidiaries MorphoSys UK Ltd., MorphoSys AbD GmbH and MorphoSys US, Inc. have been transferred to Bio-Rad.

"We are delighted to have reached the closing of the transaction just a few weeks after the announcement was made. With the divestment of AbD Serotec completed, MorphoSys can devote 100% of its attention to building value in its core therapeutics business," commented Jens Holstein, Chief Financial Officer of MorphoSys AG.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MorphoSys Announces Clinical Milestone for Start of Bayer's Phase 2 Trial
Phase 2 trial designed to support registration of anetumab ravtansine.
Wednesday, January 27, 2016
MorphoSys Publishes Update on MOR202 in Multiple Myeloma
First data from final 16 mg/kg dose escalation cohort and combination with immunomodulatory drugs show encouraging activity.
Thursday, September 24, 2015
MorphoSys to Receive Milestone Payment for Guselkumab Program
Company initiates phase 2 clinical trial in psoriatic arthritis with the HuCAL antibody.
Tuesday, April 14, 2015
MorphoSys Nominates Three New Candidates for Supervisory Board
Company has nominated Ms. Wendy Johnson, Mr. Klaus Kühn and Dr. Frank Morich.
Tuesday, March 31, 2015
MorphoSys and Celgene Mutually Agree to End MOR202 Collaboration
MorphoSys regains rights to MOR202 antibody against CD38 and updates its financial guidance for 2015.
Friday, March 27, 2015
MorphoSys Provides Update on the Company's Proprietary Drug Portfolio
Early-stage portfolio now fully Ylanthia-based, includes programs with Merck Serono as well as first anti-GPCR programs.
Tuesday, July 29, 2014
MorphoSys Strengthens Clinical Development Organization with Three Management Appointments
Appointment of Dr. Gabriele Elbl, Dr. Ludger Langer and Dr. Steffen Heeger.
Monday, December 23, 2013
MorphoSys Announces Additional Clinical Trial of MOR208
Phase 2 study in CLL will evaluate MOR208 in combination with lenalidomide.
Wednesday, December 11, 2013
MorphoSys Strengthens European Patent Position on Anti-CD19 Cancer Program MOR208
New patent has a scheduled expiry date in 2027.
Tuesday, December 03, 2013
MorphoSys Strengthens Patent Position on anti-CD19 Cancer Program MOR208
New patent covers the antibody's protein sequence.
Tuesday, October 22, 2013
MorphoSys and Xencor Provide Update on Phase 1/2a Trial in CLL/SLL for MOR208
Extended treatment resulted in higher overall response rate.
Tuesday, October 08, 2013
MorphoSys Collaborator to Start Pivotal Study with Bimagrumab
MorphoSys to receive clinical milestone payment.
Thursday, October 03, 2013
MorphoSys Receives Two Phase 2 Milestone Payments from Janssen
MOR202 in phase 1/2a trial for multiple myeloma.
Tuesday, September 17, 2013
MorphoSys Closes on the Alliance with Celgene for MOR202 and Increases Financial Guidance
Celgene acquires 3.4 % equity stake via a capital increase.
Monday, August 12, 2013
MorphoSys AG Reports Results for the First Six Months of 2013
Results strongly impacted by MOR103 licensing agreement with GSK.
Monday, August 05, 2013
Scientific News
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
Vaccinations Are More Effective When Administered In The Morning
Research from the University of Birmingham shows that influenza vaccinations have more protective responses when administered in the morning.
Secrets of a Deadly Virus Family Revealed
Scripps Research scientists uncover the glycoprotein structure of LCMV. The findings could guide development of treatments for Lassa fever.
Cytokine Triggers Immune Response at Expense of Blood Renewal
Research highlights promise of Anti-IL-1 drugs to treat chronic inflammatory disease.
Reduced Immune Response Causes Flu Deaths in Older Adults
Yale study suggests that immune response to flu causes death in older people, not the virus.
Exposure To Routine Viruses Makes Mice Better Test Subjects
Study shows that infections make mouse immune system act more like that in humans.
Immune Booster Tested in Advanced Merkel Cell Cancer
The immunotherapy drug produced durable responses in many patients.
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
Pandemic E. coli Strain Cloaks its Stealth Strategies
Antibiotic resistance and weakened immunity only partially explain persistent, harmful infection.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!